Angiostatin inhibits and regresses corneal neovascularization

Balamurali K. Ambati, Antonia M. Joussen, Jayakrishna Ambati, Yasufumi Moromizato, Chandan Guha, Kashi Javaherian, Stephen Gillies, Michael S. O'Reilly, Anthony P. Adamis

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Objective: To determine the ability of angiostatin and the angiostatin-producing low-metastatic (LM) clone of Lewis lung carcinoma (LLC) to inhibit and regress corneal neovascularization, as compared with the nonangiostatin-producing high-metastatic (HM) clone. Methods: Three groups of C57BL6/J mice underwent chemical and mechanical denudation of corneal and limbal epithelium. One group remained tumor free while the other 2 were implanted with LLC cells (either the HM or LM clones) subcutaneously the day before, 2 weeks after, or 4 weeks after denudation. Corneas were harvested 2 weeks after tumor implantation (at 2, 4, and 6 weeks after denudation for tumor-free mice). Neovascularization was quantified by CD31 immunostaining. In a second experiment, recombinant angiostatin was delivered continuously for 2 weeks via an osmotic pump in mice with established corneal neovascularization. Results: The mean percentages of neovascularized corneal area in mice 2 weeks after LM-LLC implantation were 4.6%, 3.7%, and 37.0%, at 2, 4, and 6 weeks after scraping, respectively. In contrast, in the mice implanted with HM-LLC, the corresponding values were 45.4% (P=.01), 90.1% (P=.03), and 80.3% (P=.005). For tumor-free mice, the corresponding values were 62.0% (P=.003), 68.9% (P=.03), and 59.3% (P=.06). Mice implanted with angiostatin pumps had a 37.7% neovascularized corneal area 2 weeks after implantation and 4 weeks after scraping while mice implanted with sham pumps had 60.5% (P=.007). Conclusion: Angiostatin inhibits and regresses corneal neovascularization induced by mechanical and alkali corneal injury. Clinical Relevance: This appears to be the first evidence of biologically induced regression of corneal neovascularization, and the first direct demonstration of angiostatin-induced regression of neovascularization in any tissue.

Original languageEnglish (US)
Pages (from-to)1063-1068
Number of pages6
JournalArchives of Ophthalmology
Volume120
Issue number8
StatePublished - 2002

Fingerprint

Angiostatins
Corneal Neovascularization
Lewis Lung Carcinoma
Clone Cells
Neoplasms
Corneal Epithelium
Alkalies
Cornea

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Ambati, B. K., Joussen, A. M., Ambati, J., Moromizato, Y., Guha, C., Javaherian, K., ... Adamis, A. P. (2002). Angiostatin inhibits and regresses corneal neovascularization. Archives of Ophthalmology, 120(8), 1063-1068.

Angiostatin inhibits and regresses corneal neovascularization. / Ambati, Balamurali K.; Joussen, Antonia M.; Ambati, Jayakrishna; Moromizato, Yasufumi; Guha, Chandan; Javaherian, Kashi; Gillies, Stephen; O'Reilly, Michael S.; Adamis, Anthony P.

In: Archives of Ophthalmology, Vol. 120, No. 8, 2002, p. 1063-1068.

Research output: Contribution to journalArticle

Ambati, BK, Joussen, AM, Ambati, J, Moromizato, Y, Guha, C, Javaherian, K, Gillies, S, O'Reilly, MS & Adamis, AP 2002, 'Angiostatin inhibits and regresses corneal neovascularization', Archives of Ophthalmology, vol. 120, no. 8, pp. 1063-1068.
Ambati BK, Joussen AM, Ambati J, Moromizato Y, Guha C, Javaherian K et al. Angiostatin inhibits and regresses corneal neovascularization. Archives of Ophthalmology. 2002;120(8):1063-1068.
Ambati, Balamurali K. ; Joussen, Antonia M. ; Ambati, Jayakrishna ; Moromizato, Yasufumi ; Guha, Chandan ; Javaherian, Kashi ; Gillies, Stephen ; O'Reilly, Michael S. ; Adamis, Anthony P. / Angiostatin inhibits and regresses corneal neovascularization. In: Archives of Ophthalmology. 2002 ; Vol. 120, No. 8. pp. 1063-1068.
@article{640e692fd6d749a398025f633b5331f4,
title = "Angiostatin inhibits and regresses corneal neovascularization",
abstract = "Objective: To determine the ability of angiostatin and the angiostatin-producing low-metastatic (LM) clone of Lewis lung carcinoma (LLC) to inhibit and regress corneal neovascularization, as compared with the nonangiostatin-producing high-metastatic (HM) clone. Methods: Three groups of C57BL6/J mice underwent chemical and mechanical denudation of corneal and limbal epithelium. One group remained tumor free while the other 2 were implanted with LLC cells (either the HM or LM clones) subcutaneously the day before, 2 weeks after, or 4 weeks after denudation. Corneas were harvested 2 weeks after tumor implantation (at 2, 4, and 6 weeks after denudation for tumor-free mice). Neovascularization was quantified by CD31 immunostaining. In a second experiment, recombinant angiostatin was delivered continuously for 2 weeks via an osmotic pump in mice with established corneal neovascularization. Results: The mean percentages of neovascularized corneal area in mice 2 weeks after LM-LLC implantation were 4.6{\%}, 3.7{\%}, and 37.0{\%}, at 2, 4, and 6 weeks after scraping, respectively. In contrast, in the mice implanted with HM-LLC, the corresponding values were 45.4{\%} (P=.01), 90.1{\%} (P=.03), and 80.3{\%} (P=.005). For tumor-free mice, the corresponding values were 62.0{\%} (P=.003), 68.9{\%} (P=.03), and 59.3{\%} (P=.06). Mice implanted with angiostatin pumps had a 37.7{\%} neovascularized corneal area 2 weeks after implantation and 4 weeks after scraping while mice implanted with sham pumps had 60.5{\%} (P=.007). Conclusion: Angiostatin inhibits and regresses corneal neovascularization induced by mechanical and alkali corneal injury. Clinical Relevance: This appears to be the first evidence of biologically induced regression of corneal neovascularization, and the first direct demonstration of angiostatin-induced regression of neovascularization in any tissue.",
author = "Ambati, {Balamurali K.} and Joussen, {Antonia M.} and Jayakrishna Ambati and Yasufumi Moromizato and Chandan Guha and Kashi Javaherian and Stephen Gillies and O'Reilly, {Michael S.} and Adamis, {Anthony P.}",
year = "2002",
language = "English (US)",
volume = "120",
pages = "1063--1068",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Angiostatin inhibits and regresses corneal neovascularization

AU - Ambati, Balamurali K.

AU - Joussen, Antonia M.

AU - Ambati, Jayakrishna

AU - Moromizato, Yasufumi

AU - Guha, Chandan

AU - Javaherian, Kashi

AU - Gillies, Stephen

AU - O'Reilly, Michael S.

AU - Adamis, Anthony P.

PY - 2002

Y1 - 2002

N2 - Objective: To determine the ability of angiostatin and the angiostatin-producing low-metastatic (LM) clone of Lewis lung carcinoma (LLC) to inhibit and regress corneal neovascularization, as compared with the nonangiostatin-producing high-metastatic (HM) clone. Methods: Three groups of C57BL6/J mice underwent chemical and mechanical denudation of corneal and limbal epithelium. One group remained tumor free while the other 2 were implanted with LLC cells (either the HM or LM clones) subcutaneously the day before, 2 weeks after, or 4 weeks after denudation. Corneas were harvested 2 weeks after tumor implantation (at 2, 4, and 6 weeks after denudation for tumor-free mice). Neovascularization was quantified by CD31 immunostaining. In a second experiment, recombinant angiostatin was delivered continuously for 2 weeks via an osmotic pump in mice with established corneal neovascularization. Results: The mean percentages of neovascularized corneal area in mice 2 weeks after LM-LLC implantation were 4.6%, 3.7%, and 37.0%, at 2, 4, and 6 weeks after scraping, respectively. In contrast, in the mice implanted with HM-LLC, the corresponding values were 45.4% (P=.01), 90.1% (P=.03), and 80.3% (P=.005). For tumor-free mice, the corresponding values were 62.0% (P=.003), 68.9% (P=.03), and 59.3% (P=.06). Mice implanted with angiostatin pumps had a 37.7% neovascularized corneal area 2 weeks after implantation and 4 weeks after scraping while mice implanted with sham pumps had 60.5% (P=.007). Conclusion: Angiostatin inhibits and regresses corneal neovascularization induced by mechanical and alkali corneal injury. Clinical Relevance: This appears to be the first evidence of biologically induced regression of corneal neovascularization, and the first direct demonstration of angiostatin-induced regression of neovascularization in any tissue.

AB - Objective: To determine the ability of angiostatin and the angiostatin-producing low-metastatic (LM) clone of Lewis lung carcinoma (LLC) to inhibit and regress corneal neovascularization, as compared with the nonangiostatin-producing high-metastatic (HM) clone. Methods: Three groups of C57BL6/J mice underwent chemical and mechanical denudation of corneal and limbal epithelium. One group remained tumor free while the other 2 were implanted with LLC cells (either the HM or LM clones) subcutaneously the day before, 2 weeks after, or 4 weeks after denudation. Corneas were harvested 2 weeks after tumor implantation (at 2, 4, and 6 weeks after denudation for tumor-free mice). Neovascularization was quantified by CD31 immunostaining. In a second experiment, recombinant angiostatin was delivered continuously for 2 weeks via an osmotic pump in mice with established corneal neovascularization. Results: The mean percentages of neovascularized corneal area in mice 2 weeks after LM-LLC implantation were 4.6%, 3.7%, and 37.0%, at 2, 4, and 6 weeks after scraping, respectively. In contrast, in the mice implanted with HM-LLC, the corresponding values were 45.4% (P=.01), 90.1% (P=.03), and 80.3% (P=.005). For tumor-free mice, the corresponding values were 62.0% (P=.003), 68.9% (P=.03), and 59.3% (P=.06). Mice implanted with angiostatin pumps had a 37.7% neovascularized corneal area 2 weeks after implantation and 4 weeks after scraping while mice implanted with sham pumps had 60.5% (P=.007). Conclusion: Angiostatin inhibits and regresses corneal neovascularization induced by mechanical and alkali corneal injury. Clinical Relevance: This appears to be the first evidence of biologically induced regression of corneal neovascularization, and the first direct demonstration of angiostatin-induced regression of neovascularization in any tissue.

UR - http://www.scopus.com/inward/record.url?scp=0036336988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036336988&partnerID=8YFLogxK

M3 - Article

VL - 120

SP - 1063

EP - 1068

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 8

ER -